|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
ZA737247B
(en)
|
1972-09-29 |
1975-04-30 |
Ayerst Mckenna & Harrison |
Rapamycin and process of preparation
|
|
GB2116183B
(en)
|
1982-03-03 |
1985-06-05 |
Genentech Inc |
Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
|
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
DE768377T1
(de)
|
1988-09-02 |
1998-01-02 |
Dyax Corp |
Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
ES2139598T3
(es)
|
1990-07-10 |
2000-02-16 |
Medical Res Council |
Procedimientos para la produccion de miembros de parejas de union especifica.
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
CA2095633C
(en)
|
1990-12-03 |
2003-02-04 |
Lisa J. Garrard |
Enrichment method for variant proteins with altered binding properties
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
ES2096749T3
(es)
|
1990-12-14 |
1997-03-16 |
Cell Genesys Inc |
Cadenas quimericas para vias de transduccion de señal asociada a un receptor.
|
|
EP1279731B1
(en)
|
1991-03-01 |
2007-05-30 |
Dyax Corporation |
Process for the development of binding mini-proteins
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
IE920716A1
(en)
|
1991-03-07 |
1992-09-09 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
DE69233367T2
(de)
|
1991-04-10 |
2005-05-25 |
The Scripps Research Institute, La Jolla |
Bibliotheken heterodimerer rezeptoren mittels phagemiden
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
|
GB9125768D0
(en)
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
DE69330523T4
(de)
|
1992-08-21 |
2012-08-23 |
Vrije Universiteit Brussel |
Immunoglobuline ohne leichte ketten
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
US7211259B1
(en)
|
1993-05-07 |
2007-05-01 |
Immunex Corporation |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides
|
|
CA2175215C
(en)
|
1993-11-19 |
2008-06-03 |
Yat Sun Or |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
|
SG64372A1
(en)
|
1993-12-17 |
1999-04-27 |
Novartis Ag |
Rapamycin derivatives
|
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
|
PT758394E
(pt)
|
1994-05-02 |
2003-04-30 |
Bernd Groner |
Proteina bifuncional sua preparacao e utilizacao
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
ATE297986T1
(de)
|
1995-02-24 |
2005-07-15 |
Gen Hospital Corp |
Neuorientierung der zellulären immunität durch rezeptorchimären
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
KR100400620B1
(ko)
|
1995-06-09 |
2004-02-18 |
노파르티스 아게 |
라파마이신유도체
|
|
FR2736550B1
(fr)
|
1995-07-14 |
1998-07-24 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US5874240A
(en)
|
1996-03-15 |
1999-02-23 |
Human Genome Sciences, Inc. |
Human 4-1BB receptor splicing variant
|
|
US6258823B1
(en)
|
1996-07-12 |
2001-07-10 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
EP1947183B1
(en)
|
1996-08-16 |
2013-07-17 |
Merck Sharp & Dohme Corp. |
Mammalian cell surface antigens; related reagents
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
EP0937095A4
(en)
|
1996-10-25 |
1999-12-22 |
Cell Genesys Inc |
TARGETED CYTOLYSIS OF CANCER CELLS
|
|
WO1998024893A2
(en)
|
1996-12-03 |
1998-06-11 |
Abgenix, Inc. |
TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
|
|
PT1712623E
(pt)
|
1997-01-21 |
2011-12-21 |
Gen Hospital Corp |
Selecção de proteínas utilizando fusões de arn-proteína
|
|
CA2293632C
(en)
|
1997-06-12 |
2011-11-29 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
|
US20030060444A1
(en)
|
1997-06-25 |
2003-03-27 |
Celltech Therapeutics, Ltd. |
Cell activation process and reagents therefor
|
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6015815A
(en)
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
|
TW557297B
(en)
|
1997-09-26 |
2003-10-11 |
Abbott Lab |
Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
|
|
CA2308114A1
(en)
|
1997-10-21 |
1999-04-29 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
|
WO1999040196A1
(en)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
|
DE69925909T2
(de)
|
1998-04-15 |
2006-05-11 |
Brigham & Women's Hospital, Inc., Boston |
T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
EP1109921A4
(en)
|
1998-09-04 |
2002-08-28 |
Sloan Kettering Inst Cancer |
FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
WO2000063374A1
(en)
|
1999-04-16 |
2000-10-26 |
Celltech Therapeutics Limited |
Synthetic transmembrane components
|
|
CA2378179A1
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
|
CA2383451A1
(en)
|
1999-08-24 |
2001-03-01 |
Ariad Gene Therapeutics, Inc. |
28-epirapalogs
|
|
AU1086501A
(en)
|
1999-10-15 |
2001-04-30 |
Carnegie Institution Of Washington |
Rna interference pathway genes as tools for targeted genetic interference
|
|
GB9925848D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
WO2001062895A2
(en)
|
2000-02-24 |
2001-08-30 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
IL136511A0
(en)
|
2000-06-01 |
2001-06-14 |
Gavish Galilee Bio Appl Ltd |
Genetically engineered mhc molecules
|
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
|
AU2002220265A1
(en)
*
|
2000-11-03 |
2002-05-15 |
University Of Vermont And State Agricultural College |
Compositions for inhibiting grb7
|
|
ATE338124T1
(de)
|
2000-11-07 |
2006-09-15 |
Hope City |
Cd19-spezifische umgezielte immunzellen
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
WO2002088334A1
(en)
|
2001-04-30 |
2002-11-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
AU2002319544B2
(en)
|
2001-08-10 |
2008-07-10 |
Aberdeen University |
Antigen binding domains from fish
|
|
US20030186374A1
(en)
|
2001-10-01 |
2003-10-02 |
Hufton Simon E. |
Multi-chain eukaryotic display vectors and uses thereof
|
|
US20030148982A1
(en)
|
2001-11-13 |
2003-08-07 |
Brenner Malcolm K. |
Bi-spcific chimeric T cells
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
|
US7670781B2
(en)
|
2002-01-03 |
2010-03-02 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
|
|
PT1478648E
(pt)
|
2002-02-01 |
2014-07-15 |
Ariad Pharma Inc |
Compostos contendo fósforo e suas utilizações
|
|
GB0208104D0
(en)
|
2002-04-09 |
2002-05-22 |
Univ Dundee |
Method
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
|
CA2508660C
(en)
|
2002-12-23 |
2013-08-20 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
RU2369636C2
(ru)
|
2003-05-23 |
2009-10-10 |
Уайт |
Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
|
|
AU2004255216B2
(en)
|
2003-07-01 |
2010-08-19 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
US20050048054A1
(en)
|
2003-07-11 |
2005-03-03 |
Shino Hanabuchi |
Lymphocytes; methods
|
|
WO2005019429A2
(en)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
|
JP2007518399A
(ja)
|
2003-12-02 |
2007-07-12 |
ジェンザイム コーポレイション |
肺癌を診断および治療する組成物並びに方法
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
|
WO2006036445A2
(en)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Chimeric nk receptor and methods for treating cancer
|
|
EP1827604B1
(en)
|
2004-12-10 |
2019-11-20 |
Peter MacCallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
|
PT1866339E
(pt)
|
2005-03-25 |
2013-09-03 |
Gitr Inc |
Moléculas de ligação a gitr e suas utilizações
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
PL1907424T3
(pl)
|
2005-07-01 |
2015-12-31 |
Squibb & Sons Llc |
Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1)
|
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
|
CA2618482C
(en)
|
2005-08-19 |
2014-10-07 |
Abbott Laboratories |
Dual variable domain immunoglobin and uses thereof
|
|
PL1931645T3
(pl)
|
2005-10-07 |
2014-12-31 |
Exelixis Inc |
Pochodne N-(3-amino-chinoksalin-2-ylo)-sulfonamidu i ich zastosowanie jako inhibitorów kinazy-3 fosfatydyloinozytolu
|
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
|
WO2008045437A2
(en)
|
2006-10-09 |
2008-04-17 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
US8354509B2
(en)
|
2007-06-18 |
2013-01-15 |
Msd Oss B.V. |
Antibodies to human programmed death receptor PD-1
|
|
WO2009009116A2
(en)
|
2007-07-12 |
2009-01-15 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
|
US8359965B2
(en)
|
2007-09-17 |
2013-01-29 |
Oxford J Craig |
Apparatus and method for broad spectrum radiation attenuation
|
|
CA2700860C
(en)
*
|
2007-10-01 |
2016-07-19 |
Jonathan A. Terrett |
Human antibodies that bind mesothelin, and uses thereof
|
|
US9416165B2
(en)
|
2007-10-26 |
2016-08-16 |
The Regents Of The University Of California |
Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
|
|
WO2009097140A1
(en)
|
2008-01-30 |
2009-08-06 |
Memorial Sloan-Kettering Cancer Center |
Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
|
|
CA2715166C
(en)
|
2008-02-11 |
2017-05-16 |
Curetech Ltd. |
Monoclonal antibodies for tumor treatment
|
|
EP2262504A1
(en)
|
2008-02-21 |
2010-12-22 |
AstraZeneca AB |
Combination therapy 238
|
|
US8379824B2
(en)
|
2008-03-06 |
2013-02-19 |
At&T Intellectual Property I, Lp |
Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
ＴＧＦ-β 길항제 다중-표적 결합 단백질
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EA201500417A1
(ru)
|
2008-08-25 |
2015-11-30 |
Эмплиммьюн, Инк. |
Композиции антагонистов pd-1 и способы применения
|
|
JP2012500652A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
標的化共刺激ポリペプチドおよび癌を処置するための使用方法
|
|
PL3006459T3
(pl)
|
2008-08-26 |
2022-01-17 |
City Of Hope |
Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu
|
|
JPWO2010030002A1
(ja)
|
2008-09-12 |
2012-02-02 |
国立大学法人三重大学 |
外来性ｇｉｔｒリガンド発現細胞
|
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
|
RU2017132160A
(ru)
|
2008-12-09 |
2019-02-08 |
Дженентек, Инк. |
Антитела к pd-l1 и их применение для усиления функции t-клеток
|
|
WO2010085660A2
(en)
|
2009-01-23 |
2010-07-29 |
Roger Williams Hospital |
Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
US8679492B2
(en)
|
2009-02-23 |
2014-03-25 |
Glenmark Pharmaceuticals S.A. |
Humanized antibodies that bind to CD19 and their uses
|
|
AU2010230063B2
(en)
|
2009-03-24 |
2015-06-25 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Anti-mesothelin antibodies
|
|
CA2757485C
(en)
|
2009-04-03 |
2017-01-17 |
Dizhong Chen |
Pyrimidine substituted purine compounds as kinase (s) inhibitors
|
|
ES2668874T3
(es)
|
2009-04-30 |
2018-05-22 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Anticuerpos anti-CEACAM1 y métodos de uso de los mismos
|
|
RU2646139C1
(ru)
|
2009-09-03 |
2018-03-01 |
Мерк Шарп И Доум Корп. |
Анти-gitr-антитела
|
|
WO2011041093A1
(en)
|
2009-10-01 |
2011-04-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
CN103124743A
(zh)
|
2009-12-29 |
2013-05-29 |
新兴产品开发西雅图有限公司 |
Ron结合构建物及其使用方法
|
|
CN102134276A
(zh)
*
|
2010-01-22 |
2011-07-27 |
上海抗体药物国家工程研究中心有限公司 |
一种抗ctla-4嵌合抗体
|
|
WO2011097477A1
(en)
|
2010-02-04 |
2011-08-11 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
UY33498A
(es)
|
2010-07-09 |
2013-01-03 |
Sanofi Aventis |
Combinaciones de inhibidores de quinasas para el tratamiento de cancer
|
|
RU2013106427A
(ru)
|
2010-07-16 |
2014-08-27 |
Пирамал Энтерпрайзис Лимитед |
Замещенные имидазохинолиновые производные в качестве ингибиторов киназы
|
|
EP2596011B1
(en)
|
2010-07-21 |
2018-10-03 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a hla locus
|
|
CA2816379A1
(en)
|
2010-10-27 |
2012-05-03 |
Baylor College Of Medicine |
Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CA3102782A1
(en)
|
2010-12-14 |
2012-06-21 |
University Of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
|
|
US8911732B2
(en)
*
|
2010-12-20 |
2014-12-16 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
CN103442768A
(zh)
|
2011-01-18 |
2013-12-11 |
宾夕法尼亚大学董事会 |
治疗癌的组合物和方法
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
MX359513B
(es)
|
2011-03-23 |
2018-10-01 |
Hutchinson Fred Cancer Res |
Metodo y composiciones para inmunoterapia celular.
|
|
EP2694553B1
(en)
|
2011-04-01 |
2017-10-11 |
Memorial Sloan-Kettering Cancer Center |
T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
|
|
ES2696000T3
(es)
|
2011-04-08 |
2019-01-11 |
Us Health |
Receptores de antígenos quiméricos anti-variante III de receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer
|
|
CA2832569A1
(en)
|
2011-04-08 |
2012-10-11 |
Baylor College Of Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
CA3106285A1
(en)
|
2011-07-25 |
2013-01-31 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
|
EP3915588A1
(en)
|
2011-07-29 |
2021-12-01 |
The Trustees of the University of Pennsylvania |
Switch costimulatory receptors
|
|
MY186267A
(en)
|
2011-08-11 |
2021-07-01 |
Intellikine Llc |
Kinase inhibitor polymorphs
|
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
WO2013040577A1
(en)
|
2011-09-16 |
2013-03-21 |
The Research Foundation Of State University Of New York |
Aptamers resistant to nucleocapsid degradation
|
|
CN103946952A
(zh)
|
2011-09-16 |
2014-07-23 |
宾夕法尼亚大学董事会 |
用于治疗癌症的rna改造的t细胞
|
|
EP2755487B1
(en)
|
2011-09-16 |
2018-12-19 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
|
EP2768863B1
(en)
|
2011-10-20 |
2017-09-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Anti-cd22 chimeric antigen receptors
|
|
WO2013063419A2
(en)
*
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
WO2013074916A1
(en)
*
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
JP6385277B2
(ja)
|
2011-12-01 |
2018-09-05 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
癌治療のための抗ｃｅａｃａｍ１組換え型抗体
|
|
WO2013126720A2
(en)
*
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
|
|
ES2816450T3
(es)
|
2012-02-22 |
2021-04-05 |
Univ Pennsylvania |
Uso de CAR basados en ICOS para mejorar la actividad antitumoral y la persistencia del CAR
|
|
KR20140127816A
(ko)
*
|
2012-02-22 |
2014-11-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
|
|
WO2013126726A1
(en)
*
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
MX2014010185A
(es)
|
2012-02-22 |
2014-11-14 |
Univ Pennsylvania |
Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion.
|
|
AU2013235726B2
(en)
*
|
2012-03-23 |
2017-04-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
WO2013176772A1
(en)
|
2012-05-25 |
2013-11-28 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
EA028988B1
(ru)
|
2012-07-13 |
2018-01-31 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Способ in vitro анализа культуры генетически модифицированных т-клеток для детекции загрязнения
|
|
US20160235787A1
(en)
|
2012-07-13 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Epitope Spreading Associated with CAR T-Cells
|
|
EA201992742A3
(ru)
|
2012-07-13 |
2020-12-30 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Применение cart19 для истощения нормальных b-клеток для индукции толерантности
|
|
CN111467494B
(zh)
|
2012-07-13 |
2023-05-02 |
宾夕法尼亚大学董事会 |
对cars的抗肿瘤活性的毒性管理
|
|
KR20150030724A
(ko)
|
2012-07-13 |
2015-03-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Ｃａｒ ｔ 세포를 조절하기 위한 조성물 및 방법
|
|
ES2786263T3
(es)
|
2012-07-13 |
2020-10-09 |
Univ Pennsylvania |
Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
|
|
EP2879709B1
(en)
|
2012-07-31 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Modulation of the immune response
|
|
CN102775500A
(zh)
*
|
2012-08-03 |
2012-11-14 |
郑骏年 |
嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途
|
|
MX380109B
(es)
|
2012-08-20 |
2025-03-12 |
Fred Hutchinson Cancer Center Star |
Metodo y composiciones para inmunoterapia celular.
|
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
|
CN104955845B
(zh)
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
间皮素抗体和引起有效的抗肿瘤活性的方法
|
|
CN102875685B
(zh)
*
|
2012-09-29 |
2013-12-25 |
郑骏年 |
嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途
|
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
EP2906241B1
(en)
|
2012-10-12 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Enhancement of the immune response
|
|
CN105209621B
(zh)
|
2012-12-12 |
2021-05-25 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
EP4234696A3
(en)
|
2012-12-12 |
2023-09-06 |
The Broad Institute Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
CN103145849B
(zh)
*
|
2013-02-18 |
2014-06-11 |
冯振卿 |
嵌合抗原受体及其用途
|
|
UY35340A
(es)
|
2013-02-20 |
2014-09-30 |
Novartis Ag |
Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
|
|
EP2958943B1
(en)
|
2013-02-20 |
2019-09-11 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
AU2014366047B2
(en)
*
|
2013-12-19 |
2021-03-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
EP3119425B1
(en)
|
2014-03-15 |
2020-09-23 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
EP4406610A3
(en)
|
2014-04-07 |
2024-10-30 |
Novartis AG |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
MX390943B
(es)
|
2014-07-21 |
2025-03-21 |
Novartis Ag |
Receptores de antígeno quimérico cd33 y usos de los mismos.
|
|
US20170274014A1
(en)
|
2014-07-21 |
2017-09-28 |
Jennifer Brogdon |
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
|
|
US10568947B2
(en)
|
2014-07-21 |
2020-02-25 |
Novartis Ag |
Treatment of cancer using a CLL-1 chimeric antigen receptor
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3194585A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Sortase molecules and uses thereof
|
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
JP6839074B2
(ja)
*
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
CN114107424A
(zh)
|
2014-10-08 |
2022-03-01 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
WO2016061368A1
(en)
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
|
WO2016090034A2
(en)
*
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
|
KR20250075716A
(ko)
|
2014-12-29 |
2025-05-28 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포를 제조하는 방법
|
|
WO2016115482A1
(en)
*
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016126608A1
(en)
*
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
HUE059218T2
(hu)
|
2015-04-08 |
2022-11-28 |
Novartis Ag |
CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
SG10201912978PA
(en)
*
|
2015-07-21 |
2020-02-27 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
EP3344996A2
(en)
|
2015-09-03 |
2018-07-11 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
SG10202110257UA
(en)
|
2015-09-17 |
2021-10-28 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
EP4643874A2
(en)
|
2015-12-22 |
2025-11-05 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
AU2016382512A1
(en)
|
2015-12-30 |
2018-07-12 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
MY200337A
(en)
|
2016-10-07 |
2023-12-20 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
|
|
CN109134660B
(zh)
*
|
2017-06-16 |
2022-07-01 |
上海恒润达生生物科技股份有限公司 |
靶向Mesothelin的嵌合抗原受体并联合表达抗PD1抗体的方法及其用途
|
|
US20210038659A1
(en)
*
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
WO2022030570A1
(ja)
*
|
2020-08-06 |
2022-02-10 |
ジャスミー株式会社 |
端末装置、情報処理システム及びプログラム
|